Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Benefits of Metformin Use for Cholangiocarcinoma

  • Published : 2016.01.11
Download PDF
⟨ Previous Next ⟩

Abstract

Metformin is an oral anti-hyperglycemic agent, which is the most commonly prescribed medication in the treatment of type-2 diabetes mellitus. It is purportedly associated with a reduced risk for various cancers, mainly exerting anti-proliferation effects on various human cancer cell types, such as pancreas, prostate, breast, stomach and liver. This mini-review highlights the risk and benefit of metformin used for cholangiocarcinoma (CCA) prevention and therapy. The results indicated metformin might be a quite promising strategy CCA prevention and treatment, one mechanism being inhibition of CCA tumor growth by cell cycle arrest in both in vitro and in vivo. The AMPK/mTORC1 pathway in intrahepatic CCA cells is targeted by metformin. Furthermore, metformin inhibited CCA tumor growth via the regulation of Drosha-mediated expression of multiple carcinogenic miRNAs. The use of metformin seems to be safe in patients with cirrhosis, and provides a survival benefit. Once hepatic malignancies are already established, metformin does not offer any therapeutic potential. Clinical trials and epidemiological studies of the benefit of metformin use for CCA should be conducted. To date, whether metformin as a prospective chemotherapeutic for CCA is still questionable and waits further atttention.

Keywords

References

  1. Akamatsu N, Sugawara Y, Hashimoto D (2011). Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol, 10, 94-107.
  2. Akinyeke T, Matsumura S, Wang X, et al (2013). Metformin targets c-MYC oncogene to prevent prostate cancer. Carcinogenesis, 34, 2823-32. https://doi.org/10.1093/carcin/bgt307
  3. Alimova IN, Liu B, Fan Z, et al (2009). Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle, 8, 909-15. https://doi.org/10.4161/cc.8.6.7933
  4. Bhargava P, Jani C, Savarese D, et al (2003). Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Oncol, 17, 23-6.
  5. Bhat A, Sebastiani G, Bhat M (2015). Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol, 7, 1652-9. https://doi.org/10.4254/wjh.v7.i12.1652
  6. Bhat M, Sonenberg N, Gores GJ (2013). The mTOR pathway in hepatic malignancies. Hepatol, 58, 810-8. https://doi.org/10.1002/hep.26323
  7. Chaiteerakij R, Yang JD, Harmsen WS, et al (2013). Risk factors for intrahepatic cholangiocarcinoma: association be- tween metformin use and reduced cancer risk. Hepatol, 57, 648-55. https://doi.org/10.1002/hep.26092
  8. Chapman R (1999). Risk factors for biliary tract carcinogenesis. Ann Oncol, 10, 308-11. https://doi.org/10.1023/A:1008313809752
  9. Chang AH, Parsonnet J (2010). Role of bacteria in oncogenesis. Clin Microb Rev, 23, 837-7. https://doi.org/10.1128/CMR.00012-10
  10. Choi C, Choi I, Seo J, et al (2000). Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol, 23, 425-8. https://doi.org/10.1097/00000421-200008000-00023
  11. Dayton M, Longmire W, Tompkins R (1983). Caroli's Disease: a premalignant condition? Am J Surg, 145, 41-8. https://doi.org/10.1016/0002-9610(83)90164-2
  12. Donato F, Gelatti U, Tagger A, et al (2001). Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control, 12, 959-64. https://doi.org/10.1023/A:1013747228572
  13. Giuliani F, Gebbia V, Maiello E, et al (2006). Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol, 17, 73-7.
  14. Green A, Uttaravichien T, Bhudhisawasdi V, et al. (1991). Cholangiocarcinoma in north east Thailand. A hospital-based study. Trop Geogr Med, 43, 193-8.
  15. Herrold KM (1967). Histogenesis of malignant liver tumors induced by dimethylnitrosamine. An experimental study in Syrian hamsters. J Natl Cancer Inst, 39, 1099-111.
  16. IARC. (1994). Infection with liver flukes (Opisthorchis viverrini, Opisthorchis felineus and Clonrochis sinensis). IARC Monogr Eval Carcinog Risks of Hum, 61, 121-75.
  17. Jiang X, Ma N, Wang D, et al (2015). Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma. Oncotarget, 6, 3178-94. https://doi.org/10.18632/oncotarget.3063
  18. Jing W, Jin G, Zhou X, et al (2012). Diabetes mellitus and increased risk of cholangiocarcinoma: a meta-analysis. Eur J Cancer Prev, 21, 24-31. https://doi.org/10.1097/CEJ.0b013e3283481d89
  19. Kato K, Gong J, Iwama H, et al (2012). The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther, 11, 549-60. https://doi.org/10.1158/1535-7163.MCT-11-0594
  20. Knox J, Hedley D, Oza A, et al (2005). Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol, 23, 2332-8. https://doi.org/10.1200/JCO.2005.51.008
  21. Landis S, Murray T, Bolden S, et al(1998). Cancer statistics, 1998. CA Cancer J Clin, 48, 6-29. https://doi.org/10.3322/canjclin.48.1.6
  22. Lee S, Kim M, Lee S, et al (2004). Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer, 100, 783-93. https://doi.org/10.1002/cncr.20031
  23. Lee C, Wu C, Chen G (2002). What is the impact of coexistence of hepatolithiasis on cholangiocarcinoma? J Gastroenterol Hepatol, 17, 1015-20. https://doi.org/10.1046/j.1440-1746.2002.02779.x
  24. Ling S, Feng T, Ke Q, et al (2014). Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines. Oncol Rep, 31, 2611-8. https://doi.org/10.3892/or.2014.3151
  25. Lipsett P, Pitt H, Colombani P, et al (1994). Choledochal cyst disease. A changing pattern of presentation. Ann Surg, 220, 644-52. https://doi.org/10.1097/00000658-199411000-00007
  26. Maksimova GA, Zhukova NA, Kashina EV, et al (2015). Role of Opisthorchis felineus on induction of bile duct cancer. Parazitologiia, 49, 3-11.
  27. Mecklin J, Jarvinen H, Virolainen M (1992). The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer, 69, 1112-4.
  28. Migasena P, Changbumrung S (1974). The role of nitrosamines in the cause of primary carcinoma. J Med Assoc Thai, 57, 175-8.
  29. Migasena P, Reaunsuwan W, Changbumrung S (1980). Nitrates and nitrites in local Thai preserved protein foods. J Med Assoc Thai, 63, 500-5.
  30. Mitacek EJ, Brunnemann KD, Hoffmann D, et al (1999). Volatile nitrosamines and tobacco- specific nitrosamines in the smoke of Thai cigarettes: a risk factor for lung cancer and a suspected risk factor for liver cancer in Thailand. Carcinogenesis, 20, 133-7. https://doi.org/10.1093/carcin/20.1.133
  31. Nair V, Pathi S, Jutooru I, et al (2013). Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors. Carcinogenesis, 34, 2870-79. https://doi.org/10.1093/carcin/bgt231
  32. Palmer WC, Patel T (2012). Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol, 57, 69-76. https://doi.org/10.1016/j.jhep.2012.02.022
  33. Park J, Oh S, Kim S, et al (2005). Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study. Jpn J Clin Oncol, 35, 68-73. https://doi.org/10.1093/jjco/hyi021
  34. Patel T (2002). Worldwide trends in mortality from biliary tract malignancies. BMC Cancer, 2, 10. https://doi.org/10.1186/1471-2407-2-10
  35. Pernicova I, Korbonits M (2014). Metformin mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol, 10, 143-56. https://doi.org/10.1038/nrendo.2013.256
  36. Petrushev B, Tomuleasa C, Soritau O, et al (2012). Metformin plus PIAF combination chemotherapy for hepatocellular carcinoma. Exp Oncol, 34, 17-24.
  37. Philip P, Mahoney M, Allmer C, et al (2006). Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol, 24, 3069-74. https://doi.org/10.1200/JCO.2005.05.3579
  38. Ren HB, Yu T, Liu C, et al (2011). Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis. Cancer Causes Control, 22, 837-47. https://doi.org/10.1007/s10552-011-9754-3
  39. Rosen CB, Heimbach JK, Gores GJ (2008). Surgery for cholangiocarcinoma: the role of liver transplantation. Official J Inter Hepato Pancreato Biliary Assoc, 10, 186-9. https://doi.org/10.1080/13651820801992542
  40. Saengboonmee C, Seubwai W, Wongkham C, et al (2015). Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma Association of diabetes mellitus and cholangiocarcinoma. Cancer Epidemiol, 39, 274-278. https://doi.org/10.1016/j.canep.2015.04.002
  41. Sahani D, Prasad S, Tannabe K, et al (2003). Thorotrast-induced cholangiocarcinoma: case report. Abdom Imaging, 28, 72-4. https://doi.org/10.1007/s00261-001-0148-y
  42. Shaib Y, El-Serag H, Davila J (2005). Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterol, 128, 620-6. https://doi.org/10.1053/j.gastro.2004.12.048
  43. Shin HR, Oh JK, Masuyer E, et al. (2010). Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci, 101, 579-85. https://doi.org/10.1111/j.1349-7006.2009.01458.x
  44. Sorensen H, Friis S, Olsen J, et al (1998). Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatol, 28, 921-5. https://doi.org/10.1002/hep.510280404
  45. Sripa B, Yongvanit P, Pairojkul C (2005). Etiology and Pathogenesis of Cholangiocarcinoma: Introduction to the Association with Liver Fluke Infection. Srinagarind Med J, 20, 123-34
  46. Sripa B, Kaewkes S, Sithithaworn PM, et al. (2007). Liver fluke induces cholangiocarcinoma. PLoS Med, 4, 201. https://doi.org/10.1371/journal.pmed.0040201
  47. Sripa B, Kaewkes S, Intapan PM, et al (2010). Food-borne trematodiases in Southeast Asia epidemiology, pathology, clinical manifestation and control. Adv Parasitol, 72, 305-350. https://doi.org/10.1016/S0065-308X(10)72011-X
  48. Su C, Shyr Y, Lui W, et al (1997). Hepatolithiasis associated with cholangiocarcinoma. Br J Surg, 84, 969-73. https://doi.org/10.1002/bjs.1800840717
  49. Thamavit W, Bhamarapravati N, Sahaphong S, et al. (1978). Effects of dimethylnitrosamine on induction of cholangiocarcinoma in Opisthorchis viverrini-infected Syrian golden hamsters. Cancer Res, 38, 4634-9.
  50. Thunyaharn N, Promthet S, Wiangnon S, et al (2013). Survival of cholangiocarcinoma patients in northeastern Thailand after supportive treatment. Asian Pac J Cancer Prev, 14, 7029-32. https://doi.org/10.7314/APJCP.2012.14.11.7029
  51. Watanapa P, Watanapa W (2002). Liver fluke-associated cholangiocarcinoma. Br J Surg, 89, 962-70. https://doi.org/10.1046/j.1365-2168.2002.02143.x
  52. Yang Z, Zhang X, Roberts RO, et al (2015). Metformin does not improve survival of cholangiocarcinoma in persons with diabetes. Hepatol, 1.
  53. Yeo CJ, Pitt HA, Cameron JL (1990). Cholangiocarcinoma. Surg Clin North Am, 70, 1429-47. https://doi.org/10.1016/S0039-6109(16)45293-X
  54. Zhang LF, Zhao HX (2013). Diabetes mellitus and increased risk of extrahepatic cholangiocarcinoma: a meta-analysis. Hepatogastroenterol, 60, 684-7.
  55. Zhu A, Lauwers G, Tanabe K (2004). Cholangiocarcinoma in association with Thorotrast exposure. J Hepatobiliary Pancreat Surg, 11, 430-3. https://doi.org/10.1007/s00534-004-0924-5